Individual Cannabis Stocks vs Cannabis ETFs: Which Is Better for Cannabis Investors?

The most fundamental decision cannabis investors face is whether to pick individual stocks or buy diversified ETFs. Both approaches have meaningful trade-offs that depend on your investment goals, risk tolerance, time commitment, and conviction level in specific companies.

Individual cannabis stocks offer the potential for outsized returns. If you correctly identify a company like Green Thumb Industries before a major rally, your gains could far exceed the broader sector's performance. Stock picking also gives you full control over portfolio construction — you can overweight MSOs if you believe in US federal reform, or concentrate in high-margin operators if you prioritize profitability. However, single-stock risk is real and amplified in cannabis, where regulatory setbacks, dilution events, or management missteps can send any individual company down 50% or more in short order.

Cannabis ETFs provide instant diversification, which is particularly valuable in an industry where company-specific blowups are common. MSOS holds positions across most major US MSOs, meaning one bad earnings report from a single holding will not devastate your portfolio. ETFs also handle rebalancing automatically — as market caps shift, the fund adjusts holdings without requiring you to monitor and trade each position. For investors who lack the time or expertise to analyze individual cannabis financials, ETFs offer a sensible alternative.

The cost equation favors ETFs for small portfolios but may favor individual stocks at scale. Cannabis ETFs charge expense ratios between 0.60% and 0.95% annually, which compounds over time. If you invest $10,000 in MSOS with a 0.75% expense ratio, you pay roughly $75 per year in fees regardless of performance. Buying individual stocks incurs no ongoing management fee (just trading commissions, which are now zero at most brokers). However, ETFs save you the implicit cost of your time spent researching and monitoring positions.

Liquidity is another differentiator. MSOS and MJ trade on major exchanges with tight bid-ask spreads and deep order books. Many individual cannabis stocks — especially MSOs on OTC Markets — have wider spreads and lower volume, which increases trading costs and makes it harder to enter or exit large positions quickly. This OTC liquidity discount is one reason institutional investors often prefer the ETF wrapper for cannabis exposure.

Tax efficiency tilts slightly toward ETFs. Cannabis ETFs can use in-kind creation and redemption mechanisms to minimize capital gains distributions, while actively trading individual stocks may generate more taxable events. That said, cannabis ETFs have been less tax-efficient than mainstream ETFs due to the swap structures some use for OTC exposure. Consult a tax advisor if tax efficiency is a primary concern.

Finally, consider your information edge. If you follow the cannabis industry closely, attend earnings calls, and understand state-level regulatory dynamics, you may have genuine insight that justifies stock picking. If cannabis is one of many sectors in your portfolio and you check it monthly, an ETF is probably the more practical vehicle for your cannabis allocation.